Ligand Pharmaceuticals Inc LGND Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Mar 24, 2023 (filed on Mar 28, 2023)

Insider Name:

Reardon Andrew

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-300

Price:

$69.92
Feb 23, 2023 (filed on Feb 27, 2023)

Insider Name:

Espinoza Octavio

Ownership Type:

Direct Ownership

Securities:

Employee Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

16,419

Price:

--
Feb 23, 2023 (filed on Feb 27, 2023)

Insider Name:

Espinoza Octavio

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

6,046

Price:

--
Feb 23, 2023 (filed on Feb 27, 2023)

Insider Name:

Korenberg Matthew E

Ownership Type:

Direct Ownership

Securities:

Employee Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

24,628

Price:

--
Feb 23, 2023 (filed on Feb 27, 2023)

Insider Name:

Korenberg Matthew E

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

9,069

Price:

--
Feb 23, 2023 (filed on Feb 27, 2023)

Insider Name:

Reardon Andrew

Ownership Type:

Direct Ownership

Securities:

Employee Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

15,393

Price:

--
Feb 23, 2023 (filed on Feb 27, 2023)

Insider Name:

Reardon Andrew

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

5,668

Price:

--
Feb 23, 2023 (filed on Feb 27, 2023)

Insider Name:

Davis Todd C

Ownership Type:

Direct Ownership

Securities:

Employee Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

46,178

Price:

--
Feb 23, 2023 (filed on Feb 27, 2023)

Insider Name:

Davis Todd C

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

17,005

Price:

--
Feb 15, 2023 (filed on Feb 17, 2023)

Insider Name:

Korenberg Matthew E

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-2,890

Price:

$72.98

Filings by filing date

Mar 24, 2023 (filed on Mar 28, 2023)

Insider Name:

Reardon Andrew

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-300

Price:

$69.92
Feb 23, 2023 (filed on Feb 27, 2023)

Insider Name:

Espinoza Octavio

Ownership Type:

Direct Ownership

Securities:

Employee Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

16,419

Price:

--
Feb 23, 2023 (filed on Feb 27, 2023)

Insider Name:

Espinoza Octavio

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

6,046

Price:

--
Feb 23, 2023 (filed on Feb 27, 2023)

Insider Name:

Korenberg Matthew E

Ownership Type:

Direct Ownership

Securities:

Employee Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

24,628

Price:

--
Feb 23, 2023 (filed on Feb 27, 2023)

Insider Name:

Korenberg Matthew E

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

9,069

Price:

--
Feb 23, 2023 (filed on Feb 27, 2023)

Insider Name:

Reardon Andrew

Ownership Type:

Direct Ownership

Securities:

Employee Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

15,393

Price:

--
Feb 23, 2023 (filed on Feb 27, 2023)

Insider Name:

Reardon Andrew

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

5,668

Price:

--
Feb 23, 2023 (filed on Feb 27, 2023)

Insider Name:

Davis Todd C

Ownership Type:

Direct Ownership

Securities:

Employee Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

46,178

Price:

--
Feb 23, 2023 (filed on Feb 27, 2023)

Insider Name:

Davis Todd C

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

17,005

Price:

--
Feb 15, 2023 (filed on Feb 17, 2023)

Insider Name:

Korenberg Matthew E

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-2,890

Price:

$72.98

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	3911 Sorrento Valley Blvd, Suite 110 SAN DIEGO CA 92121
Tel:	N/A
Website:	https://www.ligand.com
IR:	See website

Key People

Matthew Edward Korenberg President, Chief Operating Officer	Todd C. Davis Chief Executive Officer, Director	Octavio Espinoza Chief Financial Officer

Business Overview

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. It has partnerships and license agreements with approximately 140 pharmaceutical and biotechnology companies and 400 programs are in various stages of commercialization, development, or research and are fully funded by its collaboration partners and licensees. The Company's OmniAb business segment is focused on enabling the discovery of therapeutic candidates for its partners by pairing antibody repertoires generated from its proprietary transgenic animals with its OmniAb business platform screening tools. The Company's Ligand core business segment is a biopharmaceutical business focused on developing or acquiring technologies that help pharmaceutical companies deliver and develop medicines. The OmniAb platform creates and screens diverse antibody pools and is designed to identify optimal antibodies.

Financial Overview

For the fiscal year ended 31 December 2022, Ligand Pharmaceuticals Inc revenues decreased 29% to $196.2M. Net loss before extraordinary items totaled $5.2M vs. income of $57.1M. Revenues reflect Captisol segment decrease of 36% to $104.5M, Service Revenue segment decrease of 95% to $1.1M. Net loss reflects Other operating (income) expense decrease from $37.6M (income) to $0K, SBC - General and administrative expense increase of 87% to $39.9M (expense).

Employees:	76 as of Dec 31, 2022

Reporting Currency:	U.S. Dollars
Enterprise value:	$1,122M as of Dec 31, 2022
Annual revenue (TTM):	$196.25M as of Dec 31, 2022
EBITDA (TTM):	$54.57M as of Dec 31, 2022
Net annual income (TTM):	-$5.22M as of Dec 31, 2022
Free cash flow (TTM):	$119.93M as of Dec 31, 2022
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	17,076,658 as of Feb 22, 2023
Index Membership:	S&P 600 Small Cap
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization